Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

First gene therapy for leukaemia approved

04 September 2017

By Meetal Solanki

Appeared in BioNews 916

The world's first cancer treatment which uses a patient's own genetically modified immune cells has been approved.

The treatment, called Kymriah (tisagenlecleucel), is also the first gene therapy to be approved in the USA by the Food and Drug Administration (FDA).

'We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer,' said FDA commissioner Dr Scott Gottlieb. 'New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.'

The drug is a treatment for acute lymphoblastic leukaemia (ALL), a type of cancer which causes the bone marrow to produce abnormal B or T lymphocytes (white blood cells). The National Cancer Institute estimates that approximately 3,100 patients aged 20 and younger are diagnosed with ALL each year.

Produced by Novartis, Kymriah is made from the patient's own T lymphocytes, which are filtered from the patient's blood and then genetically modified to include a gene coding for a protein called chimeric antigen receptor (CAR). The so-called CAR-T cells are then injected back in the patient, where they are able to recognise and destroy leukaemic B cells.

Kymriah has an advantage over traditional chemotherapy as it does not attack the patient's healthy cells and weaken the body's natural defences. Clinical trials with 63 paediatric and young adult patients with relapsed ALL showed an 83 percent overall remission rate within three months of treatment.

Subsequently, the FDA has approved Kymriah for ALL patients over 25 who have relapsed or have not responded to other treatments.

'Not only does Kymriah provide [patients] with a new treatment option where very limited options existed, but a treatment option that has shown promising remission and survival rates in clinical trials,' said Dr Peter Marks, director of the FDA's Centre for Biologics Evaluation and Research.

However the drug does have potentially life-threatening side effects, including inflammation and destruction of normal B cells which leaves patients prone to infections. The FDA requires hospitals that dispense Kymriah be specially certified to treat such side effects.

Although delivered as a one-time dose, Kymriah is priced at US $475,000. Dr Craig Devoe of Northwell Health Cancer Institute, New York, told AFP that he did not think the price was reasonable, and questioned how long treatment would be effective. 'Not just responding but staying in response long term is what patients want,' he said. 'We really don't know how long these cells are going to stay active.'

An application with the European Medicines Agency is expected to be filed by the end of the year, and the FDA may also approve Kymriah to treat lymphoma.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

19 October 2017 - by Jennifer Willows 
The US Food and Drug Administration have approved the world’s second gene therapy to target blood cancer...
25 September 2017 - by Sarah Gregory 
A novel gene therapy can reverse the symptoms and progression of disease in a mouse model of multiple sclerosis...
11 September 2017 - by Ebtehal Moussa 
Two trials assessing gene therapy for blood cancer have been put on hold by the US Food and Drug Administration, following a patient fatality...

17 July 2017 - by Dr Loredana Guglielmi 
A drug for leukaemia that genetically alters patients' own cells to fight cancer, has cleared a critical hurdle in gaining commercial approval...
25 January 2017 - by Dr Loredana Guglielmi 
Doctors at London's Great Ormond Street Hospital have used genome editing to successfully treat two children with leukaemia...
07 December 2016 - by Dr Loredana Guglielmi 
Researchers have developed a stem cell test that could rapidly predict how patients with acute myeloid leukaemia will respond to treatment...
22 February 2016 - by Julianna Photopoulos 
Trials using genetically engineered immune cells have shown 'extraordinary results' in treating blood cancers in terminally ill patients, say researchers...
24 February 2014 - by Chris Hardy 
Researchers trialling a gene therapy-based treatment for leukemia have said the early results go beyond anything they could have thought of in their 'wildest dreams'...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation